Related Experiment Video
Updated: May 23, 2026

Rapid Viscoelastic Characterization of Airway Mucus Using a Benchtop Rheometer
Published on: April 21, 2022
Clinical characteristics of adults with slowly progressing mucopolysaccharidosis VI: a case series
Anke Thümler1, Elke Miebach, Christina Lampe
1Department of Psychiatry, University of Mainz, Mainz, Germany.
Objective:
To assess clinical features and general health status of adult patients with mucopolysaccharidosis (MPS) VI.
Methods:
This report includes the clinical history of patients older than 18 years with slowly progressing MPS VI and the retrospective analysis of the outcomes of available data collected between September 2003 and October 2008 at the Center of Pediatric and Adolescent Medicine, University Medical Center, Johannes Gutenberg-University of Mainz, Germany. Variables included were urinary glycosaminoglycan (uGAG) level, mutation analysis, body height, forced vital capacity (FVC), 6-minute walk test, echocardiographic findings, the need for craniocervical decompression surgery, orthopaedic findings and ophthalmological assessments.
Results:
The analysis included nine patients with MPS VI aged 19-29 years. The median age at diagnosis was 12 (range 6-20) years. At the time of the assessment (median age 25 years), median uGAG was 29 (range 15-149) μg/mg creatinine and median height 152 (range 136-161) cm. All patients had a FVC below standard values, seven showed reduced endurance in the 6-minute-walk test, all had valve changes with valve replacement in three, two underwent craniocervical decompression surgery, two underwent carpal tunnel surgery, five had ear/nose/throat (ENT) interventions, seven had hip pain/dysplasia, seven had corneal clouding and two were visually impaired.
Conclusions:
Although patients with slowly progressing MPS VI are a heterogeneous group showing disease manifestations in several organs, they seem to have some typical characteristics in common. Despite the attenuated clinical course, many of these patients show severe morbidity. Therefore, early diagnosis and proper follow-up and treatment are essential.
Insights
Adult patients with mucopolysaccharidosis (MPS) VI, even with slow progression, experience significant morbidity affecting multiple organs. Early diagnosis and comprehensive management are crucial for these patients.
Area of Science:
- Medical Genetics
- Rare Diseases
- Metabolic Disorders
Background:
- Mucopolysaccharidosis (MPS) VI is a rare genetic disorder.
- Adult patients with MPS VI often present with slowly progressing disease.
- Understanding the clinical spectrum in adults is vital for management.
Purpose of the Study:
- To evaluate the clinical features and general health status of adult patients diagnosed with MPS VI.
- To identify common characteristics and severe morbidities in this population.
Main Methods:
- Retrospective analysis of clinical data from adult MPS VI patients (≥18 years).
- Inclusion of variables such as urinary glycosaminoglycan (uGAG) levels, mutation analysis, physical measurements, pulmonary function (FVC), endurance (6-minute walk test), cardiac function, and surgical interventions.
- Data collected between September 2003 and October 2008.
Main Results:
- Nine adult patients (19-29 years) with MPS VI were analyzed.
- Patients exhibited reduced forced vital capacity (FVC), decreased endurance, cardiac valve abnormalities, and orthopedic issues.
- High prevalence of corneal clouding, ENT interventions, and need for surgeries like craniocervical decompression were observed.
Conclusions:
- Adult patients with slowly progressing MPS VI, despite an attenuated course, display significant multi-organ morbidity.
- Disease manifestations are heterogeneous but share common characteristics.
- Emphasizes the critical need for early diagnosis, consistent follow-up, and timely treatment.
More Related Videos
Related Concept Videos
Lysosomal Hydrolases
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Type I Diabetes III: Clinical Manifestations
Diabetes: Symptoms, Diagnosis, and Complications
Huntington Disease l: Introduction
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations

